Ropeginterferon-Treated Patients With Polycythem... - MPN Voice

MPN Voice

10,564 members14,593 posts

Ropeginterferon-Treated Patients With Polycythemia Vera Significantly More Likely to Be Phlebotomy Free at 5 Years

Manouche profile image
5 Replies

« Additional results showed a pronounced difference in the molecular response (JAK2V617F burden) between the 2 treatment arms, with “striking superiority of ropeginterferon at month 60,” Gisslinger noted.

Specifically, the median JAK2V617F allele burden at year 5 was 8.5 in the ropeginterferon arm vs 44.4 in the control arm (P < .0001). Additionally, the percentage of patients with a JAK2V617F burden of less than 10% was 53% vs 12% in the investigative and control arms, respectively (P <.0001).

Approximately 69% of patients assigned to ropeginterferon vs 21.6% of those assigned to the control experienced a molecular response at 5 years according to ELN criteria (P <.0001) »

onclive.com/view/ropeginter...

Written by
Manouche profile image
Manouche
To view profiles and participate in discussions please or .
Read more about...
5 Replies
EmeraldA profile image
EmeraldA

Woww!

MPort profile image
MPort

Thanks for posting. So the trial compariston was the new interferon with hydrea. Then the hydrea group could switch to the new interferon. And the result was no venesections and HCT kept in right range and JAK 2 burden very low or non existant for a high proportion of the group. I wonder what the results would be if the trial was old interferon v new interferon. It is good to see that the trial had such a long time ie 5 years. That too gives hope.

Manouche profile image
Manouche in reply to MPort

There wouldn’t be a huge difference between the old and new interferon , although one would expect a significantly lower drop-out in the group treated with the new interferon.

MPort profile image
MPort in reply to Manouche

I wonder about the efficiency of the new interferon vs old. Because I am on Pegasys for about 12 years. Allele burden is 31/25% depending on the test. That's a long way from remission. So hopefully the new interferon will be significantly different. It is probably easier to get good results from the comparison with Hydrea because this doesn't reduce the Jak2 burden. I just hope the new ropeginterferon is sufficiently different and even more relevant - that we will be able to be prescribed it. Thanks for your postings on important research.

Manouche profile image
Manouche in reply to MPort

According to JJ Kiladjian you would need to be phlebotomy free for 2 consecutive years with an Allele burden below 10% to be considered in remission. You seem to slowly getting there! 🤞🏻

You may also like...

Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment

level of JAK2V617F allelic burden reduction. The results suggested that treatment of patients with...

Event-free survival in patients with polycythemia vera treated with Besremi versus best available treatment

durable hematologic and molecular responses observed with long-term ropeginterferon alfa-2b therapy...

Ropeg versus HU/BAT results after 3 years

mutant JAK2 molecular response (p<0.0001) after 36 months. Importantly, molecular response strongly...

FDA Rejects Ropeginterferon alfa-2b for Polycythemia Vera

become available for patients with polycythemia vera, the FDA has requested additional...

BESREMI ACHIEVES PATIENT-SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD-PV/CONTINUATION-PV STUDIES

Besremi arm with baseline allele burden >10%. One patient met this threshold in the control arm...